Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia

Haematologica

Volumn 95, Issue 6, 2010, Pages 989-995

  Craddock, Charles ^a,c   Nagra, Sandeep ^a   Peniket, Andrew ^b   Brookes, Cassandra ^c   Buckley, Laura ^c   Nikolousis, Emmanouil ^a   Duncan, Nick ^a   Tauro, Sudhir ^d   Yin, John ^e   Liakopoulou, Effie ^f   Kottaridis, Panos ^g   Snowden, John ^h   Milligan, Donald ⁱ   Cook, Gordon ^j   Tholouli, Eleni ^e   Littlewood, Tim ^b   Peggs, Karl ^k   Vyas, Paresh ^b   Clark, Fiona ^a,c   Cook, Mark ^a,c   Mackinnon, Stephen ^g   Russell, Nigel ^l   more..

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f CHRISTIE HOSPITAL   (United Kingdom)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

ⁱ Heart of England Hospital   (United Kingdom)

^j ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^k UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^l NOTTINGHAM CITY HOSPITAL   (United Kingdom)

more..

Author keywords

Acute myeloid leukemia; Graft versus leukemia; Reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; FLUDARABINE; MELPHALAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PREDICTION; REDUCED INTENSITY CONDITIONING; T CELL DEPLETION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953189338     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.013920     Document Type: Article

References (28)

1. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009; 301(22):2349-61.
2. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390-400.
3. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versusleukemia without myeloablative therapy. Blood. 1997;89(12):4531-6.
4. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3): 756-63.
5. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006;24(3): 444-53.
6. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant. 2007;13(4):454-62.
7. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002; 99(3):1071-8.
8. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, et al. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stemcell transplantation. Cytotherapy. 2001; 3(3):197-201.
9. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O, et al. Graft-versushost disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reducedintensity preparative regimen. Blood. 2003;102(2):470-6.
10. Blaise DP, Michel Boiron J, Faucher C, Mohty M, Bay JO, Bardoux VJ, et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer. 2005; 104(9):1931-8.
11. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, et al. Allogeneic stemcell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with highrisk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23(36): 9387-93.
12. van Besien K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B, et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009;15(5):610-7.
13. Bacigalupo A, Van Lint MT, Occhini D, Gualandi F, Lamparelli T, Sogno G, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood. 1991;77(7):1423-8.
14. Bacigalupo A, Vitale V, Corvo R, Barra S, Lamparelli T, Gualandi F, et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol. 2000;108(1):99-104.
15. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322-33.
16. Kaplan E, Meier P. Non-parametric estimates from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
17. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977;35(1):1-39.
18. Cox D. Regression Models and Life Tables. J R Stat Soc B. 1972;34 197-220.
19. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone marrow transplant. 2001;28(10):909-15.
20. Sayer HG, Kroger M, Beyer J, Kiehl M, Klein SA, Schaefer-Eckart K, et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant. 2003;31(12):1089-95.
21. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia. 2006;20(2):322-8.
22. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5675-87.
23. Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM, et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood. 2007;110(1):409-17.
24. Pagel JM, Appelbaum FR, Eary JF, Rajendran J, Fisher DR, Gooley T, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006;107(5):2184-91.
25. Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004;103(4):1548-56.
26. Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. 2008;26(4):577-84.
27. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005;11(2): 108-14.
28. Wang H, Grzywacz B, Sukovich D, McCullar V, Cao Q, Lee AB, et al. The unexpected effect of cyclosporin A on CD56+CD16-and CD56+CD16+ natural killer cell subpopulations. Blood. 2007;110 (5):1530-9.